Clinical Trials
Dive into the world of clinical trials, where medical innovations are put to the test. Discover ongoing trials, their methodologies, and results. Stay informed about the latest breakthroughs and promising treatments in development. Understand the rigorous process of bringing new therapies to market.
PFS in Patients with Platinum-Resistant Ovarian Cancer Is Not Improved by Batiraxcept
Source – Aravive The Phase III AXLerate-OC trial (NCT04300140) assessing the combination of batiraxcept with paclitaxel has not met its ...
Bavarian Nordic’s Chikungunya Vaccine Shines in Phase III Trials, Poses Strong Challenge to Valneva’s Dominance
Source – Bavarian Nordic Bavarian Nordic has achieved a significant milestone with its chikungunya virus vaccine candidate, marking its second ...
Lillyās Retevmo Outperforms Gavreto in Lung Cancer Study
Source – Eli Lilly In the ongoing rivalry between Eli Lilly and Blueprint Medicines over their RET inhibitors, Eli Lilly ...
Boehringer Launches Pivotal Trial for Liposarcoma Drug
Boehringer Ingelheim has initiated a registration trial for its investigational therapy, brigimadlin, as a potential treatment for dedifferentiated liposarcoma (DDLPS), ...
Ovarian Cancer: Upifitamab Rilsodotin Misses Primary End Point
Source – Mersana Therapeutics According to Mersana Therapeutics, the antibody-drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) did not achieve its ...
The VOYAGER Trial Illustrates the Potential of ctDNA in GIST
ctDNA analysis is a valuable tool in monitoring disease progression and tailoring treatments for patients with gastrointestinal stromal tumor (GIST), ...
Beginning of TNG260 and Pembrolizumab Study in Advanced Solid Tumors
The first patient has received a dose of TNG260 in combination with pembrolizumab (Keytruda) as part of a Phase I/II ...
Eli Lilly’s Tirzepatide Succeeds in 2 More Late-Stage Obesity Trials Ahead of FDA Decision
Source – Eli Lilly Eli Lilly continues to gather strong evidence supporting the effectiveness of tirzepatide, its dual GIP/GLP-1 agonist, ...
Merck’s V116 Vaccine Shows Positive Results in Phase III Trials
Source – Merck Merck, known as MSD outside of the United States and Canada, has announced highly encouraging initial results ...
Skyrizi Beats Placebo in Psoriasis Phase 4 Study
Source – Abbvie On July 26, 2023 AbbVie announced the publication of results from the Phase IVĀ IMMpulse study in ...
Merck and Moderna Commence Phase III Study of V940 with KEYTRUDA for High-Risk Melanoma
Source – Merck Moderna and Merck announced the commencement of the pivotal Phase III randomized V940-001 clinical trial. This trial ...
Continue to Evaluate TTFields in Pancreatic Cancer in the PANOVA-3 Trial
Source – Novocure The Phase III PANOVA-3 trial, which is assessing Tumor Treating Fields (TTFields) therapy in combination with nab-paclitaxel ...
Discontinuation of LOTIS-9 Trial: Zynlonta in Unfit DLBCL Patients
Source – ADC Therapeutics On July 20, 2023, ADC Therapeutics announced its decision to discontinue the Phase II LOTIS-9 clinical ...
KEYNOTE-A18 Trial: Primary Endpoint – Progression-Free Survival in High-Risk Cervical Cancer
Source – Merck Merck has announced a groundbreaking development in its Phase III KEYNOTE-A18 trial, also referred to as ENGOT-cx11/GOG-3047. ...
Some individuals’ cognitive deterioration may be slowed by hearing aids
Amid the focus on expensive therapies targeting amyloid for Alzheimer’s disease, a new clinical study highlights an alternative approach to ...
Pfizer Unveils Promising GBS Maternal Vaccine in New England Journal of Medicine
Source – Pfizer On July 19, Pfizer released promising data from a Phase II study of their GBS6 vaccine candidate, ...
Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC
In a Phase III study known as LASER301 (NCT04248829) and published in the Journal of Clinical Oncology, lazertinib (formerly YH25448), ...
Positive Effects of Rybrevant Plus Chemotherapy in Early EGFR Exon 20 Insertion NSCLC
Source – Johnson & Johnson The combination of amivantamab-vmjw (Rybrevant) with the chemotherapy doublet carboplatin and pemetrexed has demonstrated a ...
Maintaining Durable QOL in HER2+ Breast Cancer Patients: Trastuzumab Deruxtecan
Results published in Annals of Oncology indicate that Trastuzumab deruxtecan (T-DXd; Enhertu) showed superior health-related quality-of-life (HRQOL) outcomes compared to ...
BridgeBio Reports Improved Data for ATTR Cardiomyopathy Drug
Source – BridgeBio BridgeBio is preparing to seek FDA approval for its acoramidis drug to treat transthyretin amyloidosis (ATTR) cardiomyopathy, ...
J&Jās Rybrevant Wins in Rare Lung Cancer; Awaits Tagrisso Showdown
Source – Johnson & Johnson In 2021, Johnson & Johnson’s Rybrevant received accelerated approval from the FDA, becoming the first ...
First Wave BioPharma’s Pancreatic Enzyme Replacement Therapy Faces Hurdles, Stock Plummets
Source – First Wave BioPharma First Wave BioPharma, formerly known as AzurRx BioPharma, has faced ongoing challenges in bringing a ...
Promising Phase III Results: OCREVUS (Ocrelizumab) Subcutaneous Injection Offers Convenient and Efficient Treatment for Multiple Sclerosis
Source – Roche On 13 July Roche announced positive results from the Phase III OCARINA II trial, which investigated the ...
The Safety of THIO Sequenced With Cemiplimab in NSCLC Remains Promising
Source – MAIA Biotechnology Two patients with advanced non-small cell lung cancer (NSCLC) have not experienced disease progression for 12.2 ...
Avutometinib/Defactinib Phase III Confirmatory Study in LGSOC Completes Design
Source –Ā Verastem Oncology The FDA and Verastem Oncology have finalized the design of a Phase III clinical trial to ...
In unresectable/metastatic urothelial carcinoma, upfront nivolumab/chemotherapy prolongs survival
Source –Bristol-Myers Squibb Nivolumab plus chemotherapy showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival ...
IA Gemcitabine Provides Survival Benefit in Patients with Locally Advanced Pancreatic Cancer
Source –Ā RenovoRx The interim results of the Phase III TIGeR-PaC study (NCT03257033) presented at the 2023 European Society of ...
Long-Term Results from MIRROR Trial: KRYSTEXXA Injection Combined with Methotrexate Reveals Promising Outcomes
Source – Horizon On July 6, 2023, Horizon Therapeutics announced the publication of long-term data from the MIRROR randomized controlled ...
Pirtobrutinib Shows Promise as a Novel CLL/SLL Treatment for Patients Previously Treated with BTK Inhibitors
Source – Eli Lilly On July 6, 2023,Ā Eli Lilly and Company’s oncology unit announced that The New England Journal ...
Relapsed/Refractory Marginal Zone Lymphoma Reacts to Abivertinib
A Phase IIa trial conducted in China demonstrated that treatment with the irreversible BTK inhibitor abivertinib (Fujovee) resulted in responses ...
